TriSalus Life Sciences, Inc. (NASDAQ: TLSI)

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that seeks to transform treatment for patients with solid tumors by integrating its proprietary pressure-enabled drug delivery (PEDD) platform with standard-of-care therapies and its investigational immunotherapeutic nelitolimod, a class C Toll‑like receptor 9 agonist. The company’s PEDD technology addresses high intratumoral pressure and off‑target delivery, aiming to improve drug penetration and therapeutic efficacy in liver, pancreatic and other solid tumors. TriSalus markets the FDA‑cleared TriNav Infusion System for embolization procedures and continues to develop additional devices such as the pancreatic retrograde venous infusion (PRVI) system and the nelitolimod drug candidate for future combination therapies.

TriSalus generates revenue primarily from the sale of its FDA‑cleared TriNav Infusion System, which utilizes PEDD technology to enhance the delivery of therapeutic agents during transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) procedures. In 2025, TriNav sales amounted to $45.2 million, reflecting a year‑over‑year increase of 53.4%. The company also derives revenue from related disposable accessories and from the expansion of its PEDD‑based product line, including the TriNav FLX and TriNav XP variants, which address diverse anatomical challenges and broaden the addressable market for embolization therapies. While the pancreatic retrograde venous infusion (PRVI) device and the nelitolimod immunotherapeutic remain investigational and have not yet contributed to sales, they represent future growth opportunities.

TriSalus competes in the embolization device market against established products such as standard microcatheters, Embolix’s Sniper, and Merit Medical's Swift NINJA. Its competitive advantage lies in the proprietary PEDD mechanism, which actively modulates arterial pressure and flow to improve tumor‑to‑normal liver ratios and reduce non‑target embolization, a benefit demonstrated in multiple clinical studies and real‑world evidence analyses. The company’s intellectual property portfolio includes over 80 granted patents and pending applications covering the TriNav device, the PEDD method, and related technologies, providing a barrier to entry. Furthermore, TriSalus combines its device platform with the investigational nelitolimod agent, creating a potential combination therapy that could differentiate it from pure device competitors and open additional oncology indications.

TriSalus sells its products to hospitals and ambulatory surgery centers throughout the United States, focusing on institutions that perform high volumes of transarterial embolization procedures. The primary users of its technology are interventional radiologists who deploy the TriNav system during TARE and TACE, while medical oncologists, nursing staff, and hospital value‑analysis committees influence purchasing and adoption decisions. The company also engages with academic medical centers and research institutions to generate clinical data and support investigator‑initiated trials, further expanding its network of potential customers.